Several studies suggest that the beneficial metabolic effect
Several studies suggest that the beneficial metabolic effects of adiponectin in humans are primarily mediated by its HMW isoform. Increases in the ratio of HMW to total adiponectin, but not the total adiponectin level, correlated well with improved SCH772984 TFA sale sensitivity during treatment with the insulin sensitizing drug thiazolidinediones in both diabetic mice and patients with T2D (Pajvani et al, 2004, Waki et al, 2003). Likewise, prospective studies suggested that serum HMW adiponectin is a better marker than total adiponectin in the prediction of insulin resistance and the metabolic syndrome (Hara et al., 2006), T2D (Nakashima et al, 2006, Retnakaran et al, 2007), and endothelial dysfunction (Torigoe et al., 2007). In line with these epidemiological data, genetic evidence supports the role of HMW adiponectin as the major insulin-sensitizing form in humans. Two rare genetic mutations (G84R and G90S) within the collagenous domain led to extremely low levels of HMW adiponectin and were closely associated with insulin resistance and T2D (Waki et al., 2003). Likewise, two mutations in the globular domain (R112C and I164T) lead to a failure in the assembly of trimer and were associated with hypoadiponectinemia (Waki et al., 2003). Whether point mutations lead to conformational changes causing an aberrant phosphorylation of adiponectin impairing HWM formation needs to be further elucidated (Bueno et al., 2014).
We hypothesized that phosphorylation might also be involved in the oligomerization processes. In fact, phosphatase treatment of human serum samples and lysates from human omental adipose tissue caused an increase of HMW adiponectin. In line with these in vitro findings, we confirmed that CK1δ-mediated phosphorylation is a key regulator of adiponectin complex formation in living cells. Inhibition of CK1δ using the CK1-specific small molecule inhibitor IC261 in human SGBS adipocytes resulted in a stabilization of adiponectin multimeric complexes, while smaller complexes were down-regulated. Interestingly, treatment with IC261 caused a robust increase in basal and also insulin-stimulated glucose uptake pointing to a crucial role of CK1δ function in adipocyte metabolism. However, whether the increased glucose uptake is caused by alterations in adiponectin complex formation is not clear at this point.
With this set of in silico/in vitro and cellular data we clearly show that adiponectin is phosphorylated. Phosphorylation causes conformational changes and may therefore alter the activity, life span, or cellular location of proteins (Kennelly, 2003, Kostich et al, 2002). Our findings add another level of complexity to the regulation of adiponectin function. Since phosphorylation is a rapid protein modification occurring within minutes, we propose that it might be mainly involved in short term regulation of adiponectin complex formation.
Rutkowski and coauthors recently studied the transport of adiponectin into target organs (Rutkowski et al., 2014). HMW adiponectin is a huge protein and its size might limit the flux across the endothelial wall. Interestingly, blood samples collected from different organs like liver, heart, and tail vein of mice displayed a different complex distribution of the lower molecular weight oligomers (Rutkowski et al., 2014). Exercise as well as treatment with a PPARγ agonist had a significant impact on uptake of adiponectin into target tissues. We propose that phosphorylation-mediated regulation of adiponectin complexes might play an important role in these transport processes. However, this hypothesis needs further clarification.
Conclusions In summary, our results show for the first time that adiponectin is phosphorylated by several kinases and that site-specific phosphorylation, especially within the globular domain at sites targeted by CK1δ in vitro, seems to play an important role in modulating the complex formation, complex stability and activity of adiponectin.